FDA recommends annually, with doctor approval
BY MELANIE NGUYEN WITH DR. MICHAEL DEL JUNCO
The CDC recently recommended a new vaccine for people ages 60 and over to prevent Respiratory Syncytial Virus or RSV. This new RSV vaccine should be available in the fall of 2023. It is currently being offered by Pfizer and GlaxoSmithKline (GSK), a British-based pharmaceutical company. After approving in May, the FDA recommends that older adults receive one dose of the RSV vaccine annually. The United States is the first country to approve this vaccine with other European countries following suit.
Before getting the vaccine, patients should consult with their doctor to see if the vaccine is right for them. Medicare Part D will cover the cost of the RSV vaccine with no out-of-pocket costs to Medicare patients.
What is RSV?